Other Species / Isoforms
  PARK2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S9-p
IVFVRFNssHGFPVE
Upstream
Downstream
3 3
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • molecular association, regulation
  • phosphorylation
  • protein conformation
  • ubiquitination
Effects on Biological Processes:
  • carcinogenesis, inhibited
  • endocytosis, induced
  • signaling pathway regulation
Kinase, in vitro:
  • AMPKA1 (human)
Putative in vivo kinases:
  • AMPKA1 (human)
  • CAMK2A (human)
Treatment
  • A769662
  • cycloheximide
  • KN-93
  • metformin
  • TNF
  • Z-VAD-FMK
PARK2 (human) IVFVRFNssHGFPVE S9-p
PARK2 iso5 (human) IVFVRFNSSHGFPVE S9
PARK2 (mouse) IVFVRFNsSYGFPVE S9-p
PARK2 (rat) IVFVRFNSSYGFPVE S9
S10-p
VFVRFNssHGFPVEV
Downstream
1 1
Effects on Modified Protein
  • phosphorylation
PARK2 (human) VFVRFNssHGFPVEV S10-p
PARK2 iso5 (human) VFVRFNSSHGFPVEV S10
PARK2 (mouse) VFVRFNsSYGFPVEV S10
PARK2 (rat) VFVRFNSSYGFPVEV S10
S19-p
GFPVEVDsDTSIFQL
0 1
PARK2 (human) GFPVEVDsDTSIFQL S19-p
PARK2 iso5 (human) GFPVEVDSDTSIFQL S19
PARK2 (mouse) GFPVEVDSDTSILQL S19
PARK2 (rat) GFPVEVDSDTSIFQL S19
K27-ub
DTSIFQLkEVVAKRQ
Upstream
1 1
Treatment
  • CCCP
  • siRNA
PARK2 (human) DTSIFQLkEVVAKRQ K27-ub
PARK2 iso5 (human) DTSIFQLKEVVAKRQ K27
PARK2 (mouse) DTSILQLKEVVAKRQ K27
PARK2 (rat) DTSIFQLKEVVAKRQ K27
K48-ub
LRVIFAGkELRNDWT
Upstream
1 1
Treatment
  • CCCP
  • siRNA
PARK2 (human) LRVIFAGkELRNDWT K48-ub
PARK2 iso5 (human) LRVIFAGKELRNDWT K48
PARK2 (mouse) LRVIFAGKELPNHLT K48
PARK2 (rat) LRVIFAGKELQNHLT K48
S65-p
NCDLDQQsIVHIVQR
Upstream
Downstream
32 10
PARK2 (human)
S65-p
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • molecular association, regulation
  • protein conformation
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • autophagy, induced
  • autophagy, inhibited
  • carcinogenesis, inhibited
  • cell growth, inhibited
Kinase, in vitro:
  • PINK1 (human)
Putative in vivo kinases:
  • PINK1 (human)
Regulatory protein:
  • AMPKA1 (human)
Treatment
  • 991
  • antimycin_A
  • CCCP
  • FCCP
  • kinetin
  • oligomycin
  • potassium antimony tartrate
  • Potassium tartrate hemihydrate
  • SBI-0206965
  • siRNA
  • Trametinib
  • valinomycin
PARK2 (human) NCDLDQQsIVHIVQR S65-p
PARK2 iso5 (human) NCDLDQQSIVHIVQR S65
PARK2 (mouse) NCDLEQQsIVHIVQR S65-p
PARK2 (rat) NCDLEQQsIVHIVQR S65-p
K76-ac
IVQRPWRkGQEMNAT
1 1
PARK2 (human) IVQRPWRkGQEMNAT K76-ac
PARK2 iso5 (human) IVQRPWRKGQEMNAT K76
PARK2 (mouse) IVQRPRRRsHEtNAS R76
PARK2 (rat) IVQRPQRKSHETNAS K76
K76-ub
IVQRPWRkGQEMNAT
Upstream
1 1
Treatment
  • CCCP
  • siRNA
PARK2 (human) IVQRPWRkGQEMNAT K76-ub
PARK2 iso5 (human) IVQRPWRKGQEMNAT K76
PARK2 (mouse) IVQRPRRRsHEtNAS R76
PARK2 (rat) IVQRPQRKSHETNAS K76
G77
VQRPWRkGQEMNATG
0 2
PARK2 (human) VQRPWRkGQEMNATG G77
PARK2 iso5 (human) VQRPWRKGQEMNATG G77
PARK2 (mouse) VQRPRRRsHEtNASG S77-p
PARK2 (rat) VQRPQRKSHETNASG S77
M80
PWRkGQEMNATGGDD
0 1
PARK2 (human) PWRkGQEMNATGGDD M80
PARK2 iso5 (human) PWRKGQEMNATGGDD M80
PARK2 (mouse) PRRRsHEtNASGGDE T80-p
PARK2 (rat) PQRKSHETNASGGDK T80
S101-p
GCEREPQsLTRVDLs
Upstream
Downstream
3 2
Effects on Modified Protein
  • phosphorylation
Kinase, in vitro:
  • CK1A (human)
PARK2 (human) GCEREPQsLTRVDLs S101-p
PARK2 iso5 (human) GCEREPQSLTRVDLS S101
PARK2 (mouse) GSIWESRSLTRVDLs S101
PARK2 (rat) GSIWEPRSLTRVDLS S101
S108-p
sLTRVDLsssVLPGD
Upstream
Downstream
2 3
PARK2 (human)
S108-p
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • phosphorylation
  • ubiquitination
Effects on Biological Processes:
  • autophagy, induced
  • autophagy, inhibited
  • cell cycle regulation
Kinase, in vitro:
  • ULK1 (human)
Putative in vivo kinases:
  • ULK1 (human)
Regulatory protein:
  • AMPKA1 (human)
  • AMPKA1 (mouse)
  • AMPKA2 (mouse)
  • ERK7 (human)
Treatment
  • 991
  • antimycin_A
  • CCCP
  • INK-128
  • MK8722
  • oligomycin
  • phenformin
  • rotenone
  • SBI-0206965
  • siRNA
PARK2 (human) sLTRVDLsssVLPGD S108-p
PARK2 iso5 (human) SLTRVDLSSSVLPGD S108
PARK2 (mouse) SLTRVDLsSHTLPVD S108-p
PARK2 (rat) SLTRVDLSSHILPAD S108
S109-p
LTRVDLsssVLPGDs
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • phosphorylation
  • ubiquitination
Effects on Biological Processes:
  • autophagy, induced
PARK2 (human) LTRVDLsssVLPGDs S109-p
PARK2 iso5 (human) LTRVDLSSSVLPGDS S109
PARK2 (mouse) LTRVDLsSHTLPVDS S109
PARK2 (rat) LTRVDLSSHILPADS S109
S110-p
TRVDLsssVLPGDsV
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • phosphorylation
  • ubiquitination
Effects on Biological Processes:
  • autophagy, induced
PARK2 (human) TRVDLsssVLPGDsV S110-p
PARK2 iso5 (human) TRVDLSSSVLPGDSV S110
PARK2 (mouse) TRVDLsSHTLPVDSV H110
PARK2 (rat) TRVDLSSHILPADSV H110
S116-p
ssVLPGDsVGLAVIL
0 1
PARK2 (human) ssVLPGDsVGLAVIL S116-p
PARK2 iso5 (human) SSVLPGDSVGLAVIL S116
PARK2 (mouse) SHTLPVDSVGLAVIL S116
PARK2 (rat) SHILPADSVGLAVIL S116
S127-p
AVILHTDsRkDsPPA
Upstream
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, inhibited
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell growth, induced
  • translation, induced
Kinase, in vitro:
  • mTOR (human)
Putative in vivo kinases:
  • mTOR (human)
Treatment
  • rapamycin
  • serum
PARK2 (human) AVILHTDsRkDsPPA S127-p
PARK2 iso5 (human) AVILHTDSRKDSPPA S127
PARK2 (mouse) AVILDTDSKRDsEAA S127
PARK2 (rat) AVILDTDSKSDSEAA S127
K129-ac
ILHTDsRkDsPPAGs
Upstream
1 1
Treatment
  • mutation
PARK2 (human) ILHTDsRkDsPPAGs K129-ac
PARK2 iso5 (human) ILHTDSRKDSPPAGS K129
PARK2 (mouse) ILDTDSKRDsEAARG R129
PARK2 (rat) ILDTDSKSDSEAARG S129
S131-p
HTDsRkDsPPAGsPA
Upstream
Downstream
5 3
Effects on Modified Protein
  • enzymatic activity, inhibited
  • intracellular localization
Effects on Biological Processes:
  • apoptosis, induced
Kinase, in vitro:
  • CDK5 (human)
Putative in vivo kinases:
  • CDK5 (human)
  • P38A (human)
Regulatory protein:
  • PDE4B (human)
  • SYN1 (human)
Treatment
  • H-89
  • roflupram
  • seliciclib
PARK2 (human) HTDsRkDsPPAGsPA S131-p
PARK2 iso5 (human) HTDSRKDSPPAGSPA S131
PARK2 (mouse) DTDSKRDsEAARGPV S131-p
PARK2 (rat) DTDSKSDSEAARGPE S131
S136-p
kDsPPAGsPAGRSIy
2 2
PARK2 (human) kDsPPAGsPAGRSIy S136-p
PARK2 iso5 (human) KDSPPAGSPAGRSIY S136
PARK2 (mouse) RDsEAARGPVKPTYN G136
PARK2 (rat) SDSEAARGPEAKPTY G136
Y143-p
sPAGRSIyNSFYVYC
Upstream
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, inhibited
  • ubiquitination
Kinase, in vitro:
  • Abl (human)
Putative in vivo kinases:
  • Abl (human)
Treatment
  • DA
  • imatinib
  • MPP+
  • siRNA
PARK2 (human) sPAGRSIyNSFYVYC Y143-p
PARK2 iso5 (human) SPAGRSIYNSFYVYC Y143
PARK2 (mouse) RGPVKPTYNSFFIYC Y142
PARK2 (rat) GPEAKPTYHSFFVYC Y143
S193-p
VLIPNRMsGECQsPH
0 1
PARK2 (human) VLIPNRMsGECQsPH S193-p
PARK2 iso5 (human) VLIPNRMSGECQSPH S193
PARK2 (mouse) VLIPNRMSGECQSPD S192
PARK2 (rat) VLIPNRMSGECQSPD S193
S198-p
RMsGECQsPHCPGtS
0 1
PARK2 (human) RMsGECQsPHCPGtS S198-p
PARK2 iso5 (human) RMSGECQSPHCPGTS S198
PARK2 (mouse) RMSGECQSPDCPGTR S197
PARK2 (rat) RMSGECQSPDCPGTR S198
T204-p
QsPHCPGtSAEFFFK
0 1
PARK2 (human) QsPHCPGtSAEFFFK T204-p
PARK2 iso5 (human) QSPHCPGTSAEFFFK T204
PARK2 (mouse) QSPDCPGTRAEFFFK T203
PARK2 (rat) QSPDCPGTRAEFFFK T204
K220-ac
GAHPTSDkETSVALH
Upstream
1 1
Treatment
  • mutation
PARK2 (human) GAHPTSDkETSVALH K220-ac
PARK2 iso5 (human) GAHPTSDKETSVALH K220
PARK2 (mouse) GAHPTSDKDTSVALN K219
PARK2 (rat) GAHPTSDKDTSVALN K220
K220-ub
GAHPTSDkETSVALH
Downstream
1 0
Effects on Modified Protein
  • protein degradation
  • ubiquitination
PARK2 (human) GAHPTSDkETSVALH K220-ub
PARK2 iso5 (human) GAHPTSDKETSVALH K220
PARK2 (mouse) GAHPTSDKDTSVALN K219
PARK2 (rat) GAHPTSDKDTSVALN K220
S296-p
CVAGCPNsLIKELHH
2 1
PARK2 (human) CVAGCPNsLIKELHH S296-p
PARK2 iso5 (human) GVAGCPNSLIKELHH S315
PARK2 (mouse) CVAGCPNSLIKELHH S295
PARK2 (rat) CVAGCPNSLIKELHH S296
N313
ILGEEQYNRYQQYGA
0 1
PARK2 (human) ILGEEQYNRYQQYGA N313
PARK2 iso5 (human) ILGEEQYNRYQQYGA N332
PARK2 (mouse) ILGEEQYtRYQQYGA T312-p
PARK2 (rat) ILGEEQYNRYQQYGA N313
K349-ac
LPEPDQRkVTCEGGN
Upstream
1 1
Treatment
  • mutation
PARK2 (human) LPEPDQRkVTCEGGN K349-ac
PARK2 iso5 (human) LPEPDQRKVTCEGGN K368
PARK2 (mouse) LPEQGQRKVTCEGGN K348
PARK2 (rat) LPEQGQKKVTCEGGN K349
Y372-p
CRECKEAyHEGECsA
0 2
PARK2 (human) CRECKEAyHEGECsA Y372-p
PARK2 iso5 (human) gap -
PARK2 (mouse) CRDCKEAYHEGDCDS Y371
PARK2 (rat) CRDCKEAYHEGECDS Y372
S378-p
AyHEGECsAVFEASG
Upstream
Downstream
4 2
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
Effects on Biological Processes:
  • carcinogenesis, inhibited
  • cell cycle regulation
Kinase, in vitro:
  • CK1A (human)
Putative in vivo kinases:
  • PLK1 (human)
Treatment
  • 2-deoxyglucose
  • BI2536
  • siRNA
PARK2 (human) AyHEGECsAVFEASG S378-p
PARK2 iso5 (human) gap -
PARK2 (mouse) AYHEGDCDSLLEPSG D377
PARK2 (rat) AYHEGECDSMFEASG D378
T388-p
FEASGTTtQAyRVDE
0 2
PARK2 (human) FEASGTTtQAyRVDE T388-p
PARK2 iso5 (human) gap -
PARK2 (mouse) LEPSGATSQAYRVDK S387
PARK2 (rat) FEASGATSQAYRVDQ S388
Y391-p
SGTTtQAyRVDERAA
0 1
PARK2 (human) SGTTtQAyRVDERAA Y391-p
PARK2 iso5 (human) gap -
PARK2 (mouse) SGATSQAYRVDKRAA Y390
PARK2 (rat) SGATSQAYRVDQRAA Y391
K408-ac
ARWEAASkETIKKTT
1 1
PARK2 (human) ARWEAASkETIKKTT K408-ac
PARK2 iso5 (human) gap -
PARK2 (mouse) ARWEEASKETIKKTT K407
PARK2 (rat) ARWEEASKETIKKTT K408
K435-ub
NGGCMHMkCPQPQCR
1 1
PARK2 (human) NGGCMHMkCPQPQCR K435-ub
PARK2 iso5 (human) gap -
PARK2 (mouse) NGGCMHMKCPQPQCK K434
PARK2 (rat) NGGCMHMKCPQPQCK K435